Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programMathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models.Nucleic acid targeting: towards personalized therapy for head and neck cancer.Lessons learned from next-generation sequencing in head and neck cancerTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyCancer gene therapy using a survivin mutant adenovirusRadiation-guided gene therapy of cancer.Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.Evaluation of adenovirus capsid labeling versus transgene expressionAdvances in preclinical investigation of prostate cancer gene therapy.Current issues and future directions of oncolytic adenoviruses.Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy.Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.Developing novel oncolytic adenoviruses through bioselectionReplication properties of human adenovirus in vivo and in cultures of primary cells from different animal speciesHead and neck cancer: gene therapy approaches. Part II: genes delivered.Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.Clinical development of experimental therapies for malignant glioma.Molecular genetics of head and neck cancer.Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma.Gene therapy for the treatment of oral squamous cell carcinoma.Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes.Progress and limitations in cancer gene therapy.The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neckStrategies for reversing drug resistance.Delivery systems for pulmonary gene therapy.Advances in Gene Delivery Systems.Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancerGene therapy for malignant glioma.Tissue-specific promoters for cancer gene therapy.Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)Oncolytic viral therapies.Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro modelsExperimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission.
P2860
Q24596171-3A114BB9-21A3-4F98-95C5-B73C7D4FAF2EQ24627862-CB8287F5-9499-4A47-AC96-6E867E8EA3BBQ25257260-6EB3EFEE-42E7-4966-82DB-85B412DB1C9DQ26850237-2B3A6A19-D096-4A72-8594-10DCBAE32BE0Q27009209-4C8386FA-4B29-469C-B11F-F0147B846B8DQ27021951-DB975A14-0506-453C-AFAA-77BC9EAE67ECQ28072347-76B85A60-DF4F-404E-944F-2077D48AE221Q28360690-7AD5E51C-A5E7-4200-9FCF-E4F4331BBA14Q33251692-9645DF2B-D8CC-4E4B-8D48-B349D2C41682Q33259239-C61ADEBF-77C6-4736-A9CD-74CBD2EE5E46Q33669272-9A73B1CD-A532-43B0-8C43-C86CC2AFC73FQ33677054-7C11EC58-B540-49D9-A561-6101D9966831Q33730705-7355FFB3-E3B7-4F3A-910A-0ACD0237894CQ33857937-BDBD5303-FA2B-433B-9BD1-87A71717C39CQ33906116-FA937E6D-C030-4DD5-A3B7-C7842C3E1445Q34146469-5CBA1D90-4917-405E-BDF4-448BC0DA3DB4Q34183436-E50560D5-7721-4BCB-8739-73B81C0DDD65Q34415371-348E79C7-A469-463F-9BC8-579B30CF1B35Q34425447-4377B099-8FA9-41BC-9ABF-A55DDDE72A6DQ34471952-644353F2-1064-4D0D-BE78-76E635FC372FQ34545667-55DEDA14-4816-482F-9EF7-23D8C9149759Q34560682-884212A8-BCE9-4AAA-910C-6FAC4482385DQ34582878-2F83828F-D78B-4857-9E1A-614463BF5C70Q34782295-75916179-5105-4CA1-8783-7C5FEB9031B3Q34985771-FB9E90DE-EE1B-4E14-87E7-5EE1523AE8EAQ34993726-115A5C15-C62D-4845-9F3F-3837855283A8Q35036732-4180582C-20BC-4E51-ABA5-A9B56B428F36Q35043106-F65CB86F-DCA2-4F8E-AD26-D147E299DE63Q35051969-DE03CEE0-57A0-4013-B8CC-33B321D2F988Q35448964-D633F925-979F-42EA-AD37-19140D805AACQ35567287-D06C354F-6CFC-4B95-93A9-884B3192288DQ35627914-26A4B564-CFE4-444E-9227-2C0E750B7977Q35632772-D9720B31-2EFC-498B-92E4-9C8E50734D13Q35665175-CEAB83F7-6697-49A8-BC2E-31436197BF19Q35673628-16E152E7-B7FB-409F-9F83-43B4198EF119Q35779378-873ABDA0-5973-4969-86E9-842B410F3957Q35809215-33684C8D-CB33-416E-994C-A28FD6351F31Q35852258-D9B97C9E-161D-4ECD-8793-052ED1022F85Q35870475-514FEBC6-F20F-4B1A-A88C-94C8E6BA66ADQ35883639-52308139-C7CE-468F-85F5-3CC95194FF05
P2860
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Phase II trial of intratumoral ...... fractory head and neck cancer.
@en
type
label
Phase II trial of intratumoral ...... fractory head and neck cancer.
@en
prefLabel
Phase II trial of intratumoral ...... fractory head and neck cancer.
@en
P2093
P1476
Phase II trial of intratumoral ...... fractory head and neck cancer.
@en
P2093
A Blackburn
J Arseneau
J Nemunaitis
P304
P356
10.1200/JCO.2001.19.2.289
P407
P577
2001-01-01T00:00:00Z